Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus

Reuters

Dec 23, 2025

Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus

Lexaria Bioscience Corp. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH $(DHT)$ study arms compared to the Rybelsus® control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus®. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120399) on December 23, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2593441543"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2593441543\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2593441543?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-23 22:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2593441543","market":"fut","top_or_hot":-1,"title":"Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LEXX\">Lexaria Bioscience Corp</a>. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH <a href=\"https://laohu8.com/S/DHT\">$(DHT)$</a> study arms compared to the Rybelsus® control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus®. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LEXXW\">Lexaria Bioscience Corp</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120399) on December 23, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-23 22:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/LEXX\">Lexaria Bioscience Corp</a>. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH <a href=\"https://laohu8.com/S/DHT\">$(DHT)$</a> study arms compared to the Rybelsus® control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus®. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LEXXW\">Lexaria Bioscience Corp</a>. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120399) on December 23, 2025, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251223:nNDLrtHnp:1","article_id":"2593441543","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2593441543","pubTimestamp":1766500155,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Lexaria Bioscience Corp. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH  study arms compared to the Rybelsus control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LEXX":"Lexaria Bioscience Corp"},"translate_title":"Lexaria Bioscience在GLP-1临床研究中达到主要终点，DehydraTECH优于Rybelsus","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LEXX":0.9},"content_text":"Lexaria Bioscience Achieves Primary Endpoint in GLP-1 Clinical Study with DehydraTECH Outperforming Rybelsus\n    \n\nLexaria Bioscience Corp. has announced the public release of final results from its clinical study GLP-1-H24-4, conducted in Australia. The study focused on four DehydraTECH $(DHT)$ study arms compared to the Rybelsus® control arm, targeting improvements in safety and tolerability for oral GLP-1 medications. Lexaria reported achieving its primary endpoint, with data indicating a significant reduction in gastrointestinal side effects—by approximately half—relative to Rybelsus®. The company will now provide the full dataset to its pharmaceutical partner under an existing Material Transfer Agreement, recently extended through April 30, 2026, for further review and evaluation. Lexaria is also considering additional human clinical testing with a DehydraTECH + SNAC + semaglutide composition, building on results from previous studies. Further details on prospective research activities will be announced if and when plans are finalized.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lexaria Bioscience Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1120399) on December 23, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}